The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

The CHMP's endorsement is based on outcomes from ... Discovered and developed by the company’s scientists, Rinvoq is a selective and reversible Janus kinase inhibitor under investigation for ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...

Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.

The Scientific Advisory Group (SAG) has been called in to assist the EMA’s CHMP human medicines committee in its review of the drug, which is vying to become the first disease-modifying therapy ...

Vertex Pharma receives CHMP positive opinion for label expansion of Kaftrio in combination with ivacaftor: London Tuesday, March 4, 2025, 14:00 Hrs [IST] Vertex Pharmaceuticals, a ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

The CHMP has backed the drug as a treatment for ... at the data on the BCMA-targeted drug by its manufacturer. An EMA scientific advisory group concluded that the data available to date does ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Columvi® (glofitamab) in ...

Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even ...